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The in vitro fertilization process breaks down into three essential components: induction of
ovulation, fertilization of the oocyte, and development of embryos that are transferred into the
uterus. Problems may arise resulting in failure at any one ofthesejunctions.
In 1984, the World Congress on In Vitro Fertilization was held, looking at 9,641 laparoscopies
yielding 1,101 clinical pregnancies, with an overall pregnancy rate of 11 percent-clearly
indicating that in vitro fertilization/embryo transfer (IVF/ET) was an idea whose time had
come.
Ovulation induction is monitored by both the use of ultrasound and daily estradiol levels,
ultrasound indicating the number of oocytes that will be available for capture, and estradiol
indicating in an indirect way the quality of those oocytes. It is a major aim in each patient to
obtain at least four embryos, since this optimizes success rates. Ovulation induction at Yale is
carried out with a high-dose human menopausal gonadotropin (HMG)/human chorionic
gonadotropin (HCG) regimen. This regimen has insured us a success rate of 17 percent clinical
pregnancies per laparoscopy.
In the future, modifications will occur in the process with crvopreservation of oocytes and
embryos, and gamete manipulation. The modifications will be effected primarily to increase
pregnancy rates. Research will continue mainly to delineate better biochemical markers for
oocyte quality, but also to further explain the mystery ofimplantation.
INTRODUCTION
In 1984, a World Conference was held on in vitro fertilization. Dr. Seppala of the
University of Helsinki collected data from most of the centers performing IVF in the
world at that time. He reviewed 9,641 laparoscopies, yielding 1,101 clinical pregnan-
cies; an overall pregnancy rate per laparoscopy of 11 percent. The percentage ofmales
was 50.4 percent [1]. Because of the size of the sample, this is certainly the reference
point against which all other IVF programs must be measured (Table 1).
The in vitro fertilization (IVF) process breaks down into three essential technical
components: (1) the induction of ovulation in order to get numerous oocytes, (2) the
fertilization oftheoocytes and thedevelopment ofearly embryos in the laboratory, and
(3) the transfer ofthese embryos back into the uterus. Areas for potential failure in the
system parallel these components. Failure of ovulation can occur, in that either no
oocytes or oocytes which will not fertilize are produced; once successful induction has
occurred, oocytes must be retrieved at the optimal time for fertilization. Another area
for concern is the failureofnormal events to occur in the laboratory, including fusion of
the sperm to the oocyte membrane, failure ofthe sperm to penetrate into the ooplasm,
failure ofthe nuclei ofthe egg and sperm to fuse, and failure ofcleavage ofthe embryo
to occur. Problems may arise associated with transfer and implantation. Since so little
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TABLE 1
Type of Infertility and Success Rate [1]
Type of Infertility No. ofPregnancies/No. ofCycles Success (%) per Cycle
Primary 239/3,051 7.8a
Secondary 226/1,965 11.5a
Tubal factor 539/5,056 10.7
Endometriosis 46/562 8.2
Unknown cause 74/847 8.7
ap < 0.001 Published with permission [1]
is known about implantation in general, very few cogent conclusions can be drawn. The
aim of the in vitro fertilization/embryo transfer process is to mimic nature as best
possible within an artificial system.
INDUCTION OF OVULATION AND RETRIEVAL OF OOCYTES
The first portion of the process involves induction of ovulation. The problems
dictated include getting a number of oocytes so that a number of embryos can be
replaced, since many centers have shown that the pregnancy rate is directly propor-
tional to the number ofembryos replaced, up to the number four [2,3]. In conjunction
with this is insurance that the oocytes are at a level mature enough to be fertilized and
not too old so as to make them degenerated. This is a delicate balance to achieve. The
mode ofovulation induction used at Yale is human menopausal gonadotropin (HMG;
Pergonal, Serono Laboratories) starting on day 3 through day 8; othercombinations of
drugs for ovulation induction have been used, including clomiphene, clomiphene +
HMG, and natural cycles alone, without an apparent change in success rates [1]. In
someofthese instances, the luteinizing hormone (LH) surge is used as thetrigger point
to determine when the patient should have an ovum recovery, rather than the
exogenous trigger which, in most cases, is human chorionic gonadotropin (HCG).
Pergonal is a combination of75 mIU follicle-stimulating hormone (FSH) and 75 mIU
LH. Then, starting on day 8, daily ultrasounds are done, and once on ultrasound two
follicles >1.5 cm are found, 10,000 mIU HCG isgiven, which stimulates ovulation and
ovum maturation [4]. This is done in conjunction with estradiol/E2 values; if these
values are less than 400 pg/ml the cycle is aborted because of supposed poor follicle
quality. Another confounding variable at this point is that many follicles are at
different levels of generation, i.e., dysynchrony, so one can see a corpus luteum in an
ovary coexisting with immature follicles. This stage is dependent on the concept of
recruitment ofdifferent cohorts offollicles during a single stimulated cycle.
A major goal must be one ofovum quality, since supposedly the better the ovum,
the better the embryo, and therefore the higher the pregnancy rate. Many attempts
have been made to ascertain ovum quality, but it appears that estrogen production by
the granulosa cells ofthe follicles seems to be the best marker to date [5,6]. High basal
levels of E2 which begin to surge with HCG correlate well with the pregnancy rates in
the Yale system. When comparing patients with the surge, the pregnancy rate is 15
percent per laparoscopy as compared to patients without the surge, whose pregnancy
rate is 3 percent. Preliminary work using pure FSH to induce ovulation shows promise
of minor increases in success rates [7].
Once ovulation induction has been completed and a number of follicles that are at
the preovulatory phase have been generated, the next juncture, technically, is ovum
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capture. The classic mode of ovum capture is in the operating room where, under
general anesthesia using laparoscopy, the follicles are perforated with a needle,
transabdominally aspirated, and taken to a nearby laboratory for evaluation. Theother
major technique for ovum capture is aspiration which exclusively uses either transab-
dominal or transvaginal ultrasound. The former is done through the bladder under
ultrasonic visualization. The ovum recovery rate is slightly less for both ultrasound
groups, but pregnancy rates areessentially the same [8]. A subsetofpatients is defined
in which the adhesive disease is so extensive that the ultrasonographer or the
laparoscopist is unable to capture any ovum because the ovary is encapsulated in dense
adhesions. These patients usually require a pre-IVF/ET laparotomy in order to
suspend their ovaries, thereby making them accessible for future ovum capture [9].
OOCYTE FERTILIZATION IN THE LABORATORY
Once the ova are collected, they are taken to the laboratory where, under the
dissecting microscope, the oocytes are counted and graded. Grading is based primarily
on the cumulus mass and its dispersion. The more dispersed the cumulus mass, the
more mature the oocyte, thus facilitating penetration by spermatozoa.
Laboratories maintain various methods of culture, but the World Collaborative
Study seems to indicate that HAM-F-10 is the most common media utilized [1]. Once
the oocytes aregraded, they areeither inseminated after six hours or immature oocytes
are allowed to mature over a 24-hour period before being exposed to spermatozoa. This
discovery, that oocytes can mature in vitro, was a major breakthrough since it
increased the number offertilizable oocytes by a factor, in some instances, ofas much
as 20 percent [10,11].
The spermatozoa are prepared in most labs by a swim-up technique where the sperm
is spun down in a centrifuge and allowed to swim up into a supernatant layer ofmedia.
Supernatant containing sperm is then placed in a dish or test-tube vial in conjunction
with the oocyte; usually between 100,000 and 500,000 spermatozoa per oocyte are
utilized. The number of spermatozoa per oocyte, which was apparently critical at one
time, seems to be of little significance over 50,000. It is not true that the greater
number of spermatozoa the oocyte is exposed to, the more likely is polyspermia to
occur. Polyspermia means that more than one sperm penetrates the oocyte. Polysper-
mia occurs in approximately 16 percent ofoocytes, but not all in the same patient [12].
IVF/ET now holds promise for some infertilemales, in that men with low sperm counts
are now able to fertilize oocytes using IVF with some reproducibility. The World
Collaborative Study showed that although pregnancy rates were lower in men with low
sperm counts, it was not zero (Table 2) [1].
Much work has gone on over the past six years looking at follicular fluid in order to
find markers within this readily available substance that will predict ovum quality,
which is essential for fertility and embryo cleavage [6]. Cyclic AMP represents an
interesting aspect of this investigation since it probably influences oocyte maturity
inhibition; therefore, the lower thecyclic AMP levels in follicular fluid, the more likely
is that oocyte to be mature and therefore the more likely it is to become an embryo
[13].
EMBRYO TRANSFER AND LUTEAL PHASE
After 24 hours of incubation, the oocytes are then observed for fertilization and
cleavage and, approximately 20 hours after this, embryo transfer is performed.
Extensive work has been done in looking at the optimal time for embryo transfer; to
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TABLE 2
Quality of Semen and Success Rate in IVF [1]
Quality No. ofPregnancies/No. ofCycles Success (%) per Cycle
Normal 401/4,136 9.7a
Abnormal 60/872 6.9a
ap < 0.025 Published with permission [1]
date there is no answer to this question. The transfer process is simply done by placing
a silastic catheter into the uterine cavity through the internal os of the cervix, either
with or without a metal introducer. The embryos are then layered into the uterine
cavity and, it is hoped, implantation occurs. Very little is known about implantation;
some work has looked at two factors in regard to the endometrium, i.e., endometrial
receptivity and embryo-endometrial synchrony. This stage still remains an area of
great mystery for most clinicians working in the field of in vitro fertilization and
embryo transfer. One aspect that has been looked at in regard to factors enhancing
implantation is supplementation of the luteal phase with progesterone. Progesterone
injections seem to bethe mostcommon, withothergroups using variousotherregimens
for luteal support, including progesterone suppositories and continuous HCG injec-
tions [1].
IVF/ET OUTCOME
The evaluation of results remains paramount in importance, both for making
advances in the technology and for quality control of centers performing IVF/ET.
When looking at normal pregnancy rates if one looks at 100 ovulatory cycles, 60 of
those will show some evidence offertilization, based on very sensitive radioimmunoas-
says for ,B-HCG. Ofthese 60, 25 will turn out to be clinical pregnancies, and three of
these conceptions will turn out to be spontaneous abortions [14]. One must consider,
then, not only the clinical pregnancy rate but the viable pregnancy rate, as well. In the
World Collaborative Study, theviablepregnancy ratewas 15 percent with a 29 percent
abortion rate [1]. In our own series, we had a 17 percent pregnancy rate per
laparoscopy, with a 4 percent abortion rate [15]. Certainly, the next questions that
must be evaluated are what is the pregnancy rate per patient, not per cycle, and how
many cycles are optimum for a patient to try IVF/ET.
A major concern ofsociety and science originally was the chromosomal integrity of
these babies conceived in vitro. The World Collaborative Study, as compiled, puts to
rest most of these concerns in that the incidence of fetal anomalies and chromosomal
abnormalities seems to be, at the most, equal to if not less than the norm [1].
Problems in this area would result in theobservation that anyofthe prior events had
not occurred, or it could be demonstrated by chromosomal abnormalities. The rate of
chromosomal damage, as far as offspring are concerned, is small (Table 3).
CONCLUSIONS
In conclusion, IVF/ET represents a new technology that is quite exciting for the
reproductive endocrinologist and biologist [16]. The technological advances dictate a
number of challenges, including ovulation with an aim toward synchronization of
oocytes and normalization ofoocytes. It dictates management ofthe external milieu in
order to optimize pregnancy rates. An example of this could be the harmful effect of
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TABLE 3
Chromosome Anomalies in Spontaneous Abortions
After IVF [1]
No. Type
1 69, XXY
2 47,XX,+C
3 4 Trisomy
4 47,XY,+4
5 12 Trisomy
6 2 Trisomy
7 Triploid, malformations
8 Triploid
9 21 Trisomy
Published with permission [1]
the high estrogen levels necessitated by ovulation induction on the endometrium for
implantation. Much will be learned about implantation in the future, and perhaps this
is the next area ofactive research after oocyte quality parameters have been relatively
exhausted. Close vigilance as to results and careful attention to quality control are
paramount to any successful program.
Future considerations for IVF/ET include the use ofcryopreservation. Cryopreser-
vation has the advantages ofallowing us to utilize only four embryos per cycle, and use
the "spare" embryos in order to be replaced in subsequent cycles. This technique has
threeadvantages: (1) decreasing the numberoflaparoscopies needed by the patient; (2)
doing embryo transfers in a non-stimulated cycle, which therefore means that the
embryo does not see the abnormal hormonal milieu that we have created; and (3)
decreasing, it is hoped, the number of multiple gestations that we achieve now by
putting all embryos back. Another area of active research is further delineating
biochemical markers ofoocyte quality. Eventually, gamete and embryo manipulation
will be done in order to optimize success rates.
An exampleofsuch manipulation would be to take an embryo, split the embryo, and
therefore implant two embryos from a single embryo, creating an identical twin
gestation. This microcosmic problem has multiple ethical considerations, which have to
be, and are, dealt with on a daily basis in regard to any 1VF/ET program.
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